Welcome to our dedicated page for Senestech news (Ticker: SNES), a resource for investors and traders seeking the latest updates and insights on Senestech stock.
SenesTech, Inc. (NASDAQ: SNES) generates news as a biotechnology company focused on fertility control for rodent management. Its announcements frequently highlight developments related to ContraPest®, Evolve Rat, and Evolve Mouse Birth Control, which are described as contraceptive products for rats and mice that fit into integrated pest management programs and reduce reliance on traditional rodenticides.
Investors and observers following SNES news will see regular updates on financial performance and growth in Evolve rodent birth control products. Quarterly press releases report record revenues, gross profit margins, and the share of revenue contributed by Evolve-branded products, as well as commentary on adjusted EBITDA and cash balances. These releases often discuss progress toward profitability and the impact of multi-channel distribution strategies.
Company news also covers operational and commercial milestones. Examples include the launch of Evolve Rat Birth Control on major e-commerce platforms and home improvement retailer websites, expanded retail coverage through partners and wholesalers, and municipal pilot deployments in U.S. cities. Additional updates describe international distribution relationships, such as the appointment of the Belize Raptor Center as an official distributor following regulatory approval in Belize.
Regulatory and capital markets activities appear in SenesTech’s news flow as well. The company issues press releases on warrant exercises, gross proceeds from financings, and participation in investor conferences. For readers tracking SNES, this news page offers a way to monitor how SenesTech reports on product adoption, distribution channels, municipal and community programs, and financing events over time.
SenesTech, Inc. (NASDAQ: SNES) will announce its second quarter 2022 financial results on August 11, 2022, after market close. A conference call is scheduled for the same day at 5:00 pm ET to discuss these results. The company specializes in pest control through its proprietary contraceptive product, ContraPest, aimed at managing rat populations sustainably. Details for the teleconference and live webcast are provided for interested parties. For more information, visit their website.
SenesTech, Inc. (SNES) announced that its innovative Elevate Bait System with ContraPest, the only EPA registered birth control for rats, is now available for purchase nationwide, including California. This system targets roof rats effectively, especially in agricultural settings. Since its initial launch, the system has gained rapid traction, and CEO Ken Siegel highlighted significant customer interest following approval from the California Department of Pesticide Regulation. The product aims to reduce rat populations, which can reproduce exponentially, with the potential to eliminate infestations more efficiently.
SenesTech, Inc. (SNES) has launched the Elevate Bait System, an innovative EPA-registered birth control solution for roof rats, now available for purchase in the U.S. The system is designed for deployment in elevated indoor spaces to effectively target and control rat populations. This follows successful trials, showing a 95% reduction in rat activity on poultry farms after using ContraPest. The system allows easy maintenance and has received EPA approval, except in California. This breakthrough aims to combat the rising roof rat populations causing significant property damage and health risks.
SenesTech (NASDAQ: SNES) reported a remarkable 122% increase in first-quarter 2022 sales, reaching approximately $195,000, compared to $88,000 the previous year. The launch of the Elevate Bait System™ with ContraPest is anticipated to enhance market penetration, particularly in agriculture, targeting above-ground rat infestations. Despite revenue growth, the company experienced a net loss of $(2.3) million, up from $(1.8) million in Q1 2021. Cash reserves stand at approximately $7.2 million. CEO Ken Siegel emphasized ongoing sales success and innovative market solutions.
SenesTech, Inc. (NASDAQ: SNES) will disclose its first quarter 2022 financial results on May 12, 2022, after market close. The company will hold a conference call at 5:00 pm ET the same day to discuss the results. SenesTech specializes in rodent fertility control through its product, ContraPest, aiming to reduce rat populations sustainably. For participation details, interested parties can dial (844) 308-3351 or access a live webcast on the company's investor relations website.
SenesTech, Inc. (NASDAQ: SNES) will participate in the Lytham Partners Spring 2022 Investor Conference from April 4-7, 2022. A webcast presentation will be available on April 4 at 11:00 AM ET on the company's website and can be archived for later viewing. Management will also hold virtual one-on-one meetings during the event. SenesTech specializes in rodent fertility control and offers ContraPest, the first U.S. EPA-registered contraceptive for rats, aiming to minimize pest populations sustainably.
SenesTech (NASDAQ: SNES) reported a significant increase in its 2021 revenue, reaching approximately $600,000, up 113% year-over-year. Product sales surged 123%, supported by expanded deployments of ContraPest® in various sectors, including government and wildlife preservation. The company's customer base grew by 300%. Despite a net loss of $(8.3) million, cash reserves stood at approximately $9.3 million. The recent EPA approval of the Elevate Bait System™ is expected to enhance market penetration further.
SenesTech, Inc. (NASDAQ: SNES) is set to release its financial results for the fourth quarter and fiscal year 2021, concluding on December 31, 2021, after market close on March 29, 2022. A conference call will follow at 5:00 PM ET on the same day, allowing stakeholders to review the results. The company specializes in rodent fertility control, offering ContraPest, the only EPA-registered contraceptive targeting male and female rats. This innovative solution aims to significantly reduce rat populations sustainably.
SenesTech, Inc. (SNES) has announced the EPA approval and launch of its Elevate Bait System with ContraPest, targeting rat infestations in above-ground locations. This innovative bait system allows for easy deployment in settings such as barns and granaries, significantly reducing servicing time with its design for quick bottle replacement. With ContraPest's proven ability to reduce rat populations by 60-90%, the company expects enhanced sales, particularly in agriculture, as state registrations progress for a mid-April shipping date.
SenesTech, Inc. (NASDAQ: SNES) has announced the deployment of its ContraPest® product at a 2,500-bed medium security correctional facility, marking a significant first for pest control in major correctional settings.
ContraPest, a non-lethal rodent birth control solution, is designed to tackle complex challenges in correctional environments, achieving population reduction in rats by at least 94%. The product is capable of being deployed in various locations and seeks to expand within institutional settings. CEO Ken Siegel noted the importance of this advancement for pest management professionals.